AIM:To assess the efficacy of Quyin Koufuye in different types of psoriasis vulgaris and analyzes the relationship between efficacy and vari-ous disease-related factors,as well as its comple-mentary role in biologic therapy.METHODS:This study included a total of 396 patients with psoria-sis.Based on the patient history,participants were categorized into the biologics group(n=98),Quyin Koufuye-assisted biologics group(n=62),and Quyin Koufuye monotherapy group(n=236).Patient histo-ry data were collected,including gender,duration of illness,disease type,initial site of onset,degree of itching,recurrence status and time,smoking habits,joint pain,family history of psoriasis,nail damage,treatment plan,and PASI/BSA scores.A retrospective analysis was conducted to identify factors influencing the efficacy of Quyin Koufuye and to analyze its combined effects with biologics.RESULTS:Combining Quyin Koufuye with biologics significantly boosted the PASI90 response rate to 72.6％(P=0.014).Responders to PASI50 with Quyin Koufuye experienced longer recurrence intervals(＞6 months)than non-responders(50％vs.33.6％,A=0.045).Influencing factors included psoriasis-affect-ed body surface area(OR=0.960,P=0.000),pro-longed smoking history(OR=2.10,P=0.046),and psoriasis type(OR=2.47,P=0.015).CONCLUSION:This study underscores the synergy of Quyin Kou-fuye and biologics in treating psoriasis,particularly for longer recurrence intervals-factors like smoking history,psoriasis type,and affected body surface area impact Quyin Koufuye's efficacy.

AIM:To assess the efficacy of Quyin Koufuye in different types of psoriasis vulgaris and analyzes the relationship between efficacy and vari-ous disease-related factors,as well as its comple-mentary role in biologic therapy.METHODS:This study included a total of 396 patients with psoria-sis.Based on the patient history,participants were categorized into the biologics group(n=98),Quyin Koufuye-assisted biologics group(n=62),and Quyin Koufuye monotherapy group(n=236).Patient histo-ry data were collected,including gender,duration of illness,disease type,initial site of onset,degree of itching,recurrence status and time,smoking habits,joint pain,family history of psoriasis,nail damage,treatment plan,and PASI/BSA scores.A retrospective analysis was conducted to identify factors influencing the efficacy of Quyin Koufuye and to analyze its combined effects with biologics.RESULTS:Combining Quyin Koufuye with biologics significantly boosted the PASI90 response rate to 72.6％(P=0.014).Responders to PASI50 with Quyin Koufuye experienced longer recurrence intervals(＞6 months)than non-responders(50％vs.33.6％,A=0.045).Influencing factors included psoriasis-affect-ed body surface area(OR=0.960,P=0.000),pro-longed smoking history(OR=2.10,P=0.046),and psoriasis type(OR=2.47,P=0.015).CONCLUSION:This study underscores the synergy of Quyin Kou-fuye and biologics in treating psoriasis,particularly for longer recurrence intervals-factors like smoking history,psoriasis type,and affected body surface area impact Quyin Koufuye's efficacy.

AIM:To assess the efficacy of Quyin Koufuye in different types of psoriasis vulgaris and analyzes the relationship between efficacy and vari-ous disease-related factors,as well as its comple-mentary role in biologic therapy.METHODS:This study included a total of 396 patients with psoria-sis.Based on the patient history,participants were categorized into the biologics group(n=98),Quyin Koufuye-assisted biologics group(n=62),and Quyin Koufuye monotherapy group(n=236).Patient histo-ry data were collected,including gender,duration of illness,disease type,initial site of onset,degree of itching,recurrence status and time,smoking habits,joint pain,family history of psoriasis,nail damage,treatment plan,and PASI/BSA scores.A retrospective analysis was conducted to identify factors influencing the efficacy of Quyin Koufuye and to analyze its combined effects with biologics.RESULTS:Combining Quyin Koufuye with biologics significantly boosted the PASI90 response rate to 72.6％(P=0.014).Responders to PASI50 with Quyin Koufuye experienced longer recurrence intervals(＞6 months)than non-responders(50％vs.33.6％,A=0.045).Influencing factors included psoriasis-affect-ed body surface area(OR=0.960,P=0.000),pro-longed smoking history(OR=2.10,P=0.046),and psoriasis type(OR=2.47,P=0.015).CONCLUSION:This study underscores the synergy of Quyin Kou-fuye and biologics in treating psoriasis,particularly for longer recurrence intervals-factors like smoking history,psoriasis type,and affected body surface area impact Quyin Koufuye's efficacy.

AIM:To assess the efficacy of Quyin Koufuye in different types of psoriasis vulgaris and analyzes the relationship between efficacy and vari-ous disease-related factors,as well as its comple-mentary role in biologic therapy.METHODS:This study included a total of 396 patients with psoria-sis.Based on the patient history,participants were categorized into the biologics group(n=98),Quyin Koufuye-assisted biologics group(n=62),and Quyin Koufuye monotherapy group(n=236).Patient histo-ry data were collected,including gender,duration of illness,disease type,initial site of onset,degree of itching,recurrence status and time,smoking habits,joint pain,family history of psoriasis,nail damage,treatment plan,and PASI/BSA scores.A retrospective analysis was conducted to identify factors influencing the efficacy of Quyin Koufuye and to analyze its combined effects with biologics.RESULTS:Combining Quyin Koufuye with biologics significantly boosted the PASI90 response rate to 72.6％(P=0.014).Responders to PASI50 with Quyin Koufuye experienced longer recurrence intervals(＞6 months)than non-responders(50％vs.33.6％,A=0.045).Influencing factors included psoriasis-affect-ed body surface area(OR=0.960,P=0.000),pro-longed smoking history(OR=2.10,P=0.046),and psoriasis type(OR=2.47,P=0.015).CONCLUSION:This study underscores the synergy of Quyin Kou-fuye and biologics in treating psoriasis,particularly for longer recurrence intervals-factors like smoking history,psoriasis type,and affected body surface area impact Quyin Koufuye's efficacy.

AIM:To assess the efficacy of Quyin Koufuye in different types of psoriasis vulgaris and analyzes the relationship between efficacy and vari-ous disease-related factors,as well as its comple-mentary role in biologic therapy.METHODS:This study included a total of 396 patients with psoria-sis.Based on the patient history,participants were categorized into the biologics group(n=98),Quyin Koufuye-assisted biologics group(n=62),and Quyin Koufuye monotherapy group(n=236).Patient histo-ry data were collected,including gender,duration of illness,disease type,initial site of onset,degree of itching,recurrence status and time,smoking habits,joint pain,family history of psoriasis,nail damage,treatment plan,and PASI/BSA scores.A retrospective analysis was conducted to identify factors influencing the efficacy of Quyin Koufuye and to analyze its combined effects with biologics.RESULTS:Combining Quyin Koufuye with biologics significantly boosted the PASI90 response rate to 72.6％(P=0.014).Responders to PASI50 with Quyin Koufuye experienced longer recurrence intervals(＞6 months)than non-responders(50％vs.33.6％,A=0.045).Influencing factors included psoriasis-affect-ed body surface area(OR=0.960,P=0.000),pro-longed smoking history(OR=2.10,P=0.046),and psoriasis type(OR=2.47,P=0.015).CONCLUSION:This study underscores the synergy of Quyin Kou-fuye and biologics in treating psoriasis,particularly for longer recurrence intervals-factors like smoking history,psoriasis type,and affected body surface area impact Quyin Koufuye's efficacy.

AIM:To assess the efficacy of Quyin Koufuye in different types of psoriasis vulgaris and analyzes the relationship between efficacy and vari-ous disease-related factors,as well as its comple-mentary role in biologic therapy.METHODS:This study included a total of 396 patients with psoria-sis.Based on the patient history,participants were categorized into the biologics group(n=98),Quyin Koufuye-assisted biologics group(n=62),and Quyin Koufuye monotherapy group(n=236).Patient histo-ry data were collected,including gender,duration of illness,disease type,initial site of onset,degree of itching,recurrence status and time,smoking habits,joint pain,family history of psoriasis,nail damage,treatment plan,and PASI/BSA scores.A retrospective analysis was conducted to identify factors influencing the efficacy of Quyin Koufuye and to analyze its combined effects with biologics.RESULTS:Combining Quyin Koufuye with biologics significantly boosted the PASI90 response rate to 72.6％(P=0.014).Responders to PASI50 with Quyin Koufuye experienced longer recurrence intervals(＞6 months)than non-responders(50％vs.33.6％,A=0.045).Influencing factors included psoriasis-affect-ed body surface area(OR=0.960,P=0.000),pro-longed smoking history(OR=2.10,P=0.046),and psoriasis type(OR=2.47,P=0.015).CONCLUSION:This study underscores the synergy of Quyin Kou-fuye and biologics in treating psoriasis,particularly for longer recurrence intervals-factors like smoking history,psoriasis type,and affected body surface area impact Quyin Koufuye's efficacy.

AIM:To assess the efficacy of Quyin Koufuye in different types of psoriasis vulgaris and analyzes the relationship between efficacy and vari-ous disease-related factors,as well as its comple-mentary role in biologic therapy.METHODS:This study included a total of 396 patients with psoria-sis.Based on the patient history,participants were categorized into the biologics group(n=98),Quyin Koufuye-assisted biologics group(n=62),and Quyin Koufuye monotherapy group(n=236).Patient histo-ry data were collected,including gender,duration of illness,disease type,initial site of onset,degree of itching,recurrence status and time,smoking habits,joint pain,family history of psoriasis,nail damage,treatment plan,and PASI/BSA scores.A retrospective analysis was conducted to identify factors influencing the efficacy of Quyin Koufuye and to analyze its combined effects with biologics.RESULTS:Combining Quyin Koufuye with biologics significantly boosted the PASI90 response rate to 72.6％(P=0.014).Responders to PASI50 with Quyin Koufuye experienced longer recurrence intervals(＞6 months)than non-responders(50％vs.33.6％,A=0.045).Influencing factors included psoriasis-affect-ed body surface area(OR=0.960,P=0.000),pro-longed smoking history(OR=2.10,P=0.046),and psoriasis type(OR=2.47,P=0.015).CONCLUSION:This study underscores the synergy of Quyin Kou-fuye and biologics in treating psoriasis,particularly for longer recurrence intervals-factors like smoking history,psoriasis type,and affected body surface area impact Quyin Koufuye's efficacy.

AIM:To assess the efficacy of Quyin Koufuye in different types of psoriasis vulgaris and analyzes the relationship between efficacy and vari-ous disease-related factors,as well as its comple-mentary role in biologic therapy.METHODS:This study included a total of 396 patients with psoria-sis.Based on the patient history,participants were categorized into the biologics group(n=98),Quyin Koufuye-assisted biologics group(n=62),and Quyin Koufuye monotherapy group(n=236).Patient histo-ry data were collected,including gender,duration of illness,disease type,initial site of onset,degree of itching,recurrence status and time,smoking habits,joint pain,family history of psoriasis,nail damage,treatment plan,and PASI/BSA scores.A retrospective analysis was conducted to identify factors influencing the efficacy of Quyin Koufuye and to analyze its combined effects with biologics.RESULTS:Combining Quyin Koufuye with biologics significantly boosted the PASI90 response rate to 72.6％(P=0.014).Responders to PASI50 with Quyin Koufuye experienced longer recurrence intervals(＞6 months)than non-responders(50％vs.33.6％,A=0.045).Influencing factors included psoriasis-affect-ed body surface area(OR=0.960,P=0.000),pro-longed smoking history(OR=2.10,P=0.046),and psoriasis type(OR=2.47,P=0.015).CONCLUSION:This study underscores the synergy of Quyin Kou-fuye and biologics in treating psoriasis,particularly for longer recurrence intervals-factors like smoking history,psoriasis type,and affected body surface area impact Quyin Koufuye's efficacy.

Background::Although overnight fasting is recommended prior to endoscopic retrograde cholangiopancreatography (ERCP), the benefits and safety of high-carbohydrate fluid diet (CFD) intake 2 h before ERCP remain unclear. This study aimed to analyze whether high-CFD intake 2 h before ERCP can be safe and accelerate patients’ recovery.Methods::This prospective, multicenter, randomized controlled trial involved 15 tertiary ERCP centers. A total of 1330 patients were randomized into CFD group ( n = 665) and fasting group ( n = 665). The CFD group received 400 mL of maltodextrin orally 2 h before ERCP, while the control group abstained from food/water overnight (>6 h) before ERCP. All ERCP procedures were performed using deep sedation with intravenous propofol. The investigators were blinded but not the patients. The primary outcomes included postoperative fatigue and abdominal pain score, and the secondary outcomes included complications and changes in metabolic indicators. The outcomes were analyzed according to a modified intention-to-treat principle. Results::The post-ERCP fatigue scores were significantly lower at 4 h (4.1 ± 2.6 vs. 4.8 ± 2.8, t = 4.23, P <0.001) and 20 h (2.4 ± 2.1 vs. 3.4 ± 2.4, t= 7.94, P <0.001) in the CFD group, with least-squares mean differences of 0.48 (95% confidence interval [CI]: 0.26–0.71, P <0.001) and 0.76 (95% CI: 0.57–0.95, P <0.001), respectively. The 4-h pain scores (2.1 ± 1.7 vs. 2.2 ± 1.7, t = 2.60, P = 0.009, with a least-squares mean difference of 0.21 [95% CI: 0.05–0.37]) and positive urine ketone levels (7.7% [39/509] vs. 15.4% [82/533], χ2 = 15.13, P <0.001) were lower in the CFD group. The CFD group had significantly less cholangitis (2.1% [13/634] vs. 4.0% [26/658], χ2 = 3.99, P = 0.046) but not pancreatitis (5.5% [35/634] vs. 6.5% [43/658], χ2 = 0.59, P = 0.444). Subgroup analysis revealed that CFD reduced the incidence of complications in patients with native papilla (odds ratio [OR]: 0.61, 95% CI: 0.39–0.95, P = 0.028) in the multivariable models. Conclusion::Ingesting 400 mL of CFD 2 h before ERCP is safe, with a reduction in post-ERCP fatigue, abdominal pain, and cholangitis during recovery.Trail Registration::ClinicalTrials.gov, No. NCT03075280.